T Cell Immunogenicity, Gene Expression Profile, and Safety of Four Heterologous Prime-Boost Combinations of HIV Vaccine Candidates in Healthy Volunteers: Results of the Randomized Multi-Arm Phase I/II ANRS VRI01 Trial
Laura Richert, Jean-Daniel Lelièvre, Christine Lacabaratz, Lucile Hardel, Hakim Hocini, Aurélie Wiedemann, Frédéric Lucht, Isabelle Poizot-Martin, Claire Bauduin, Alpha Diallo, Véronique Rieux, Elodie Rouch, Mathieu Surenaud, Cécile Lefebvre, Emile Foucat, Pascaline Tisserand, Lydia Guillaumat, Mélany Durand, Boris Hejblum, Odile Launay, Rodolphe Thiébaut and Yves Lévy on behalf of the ANRS VRI01 Study Group
J Immunol May 25, 2022, ji2101076; DOI: https://doi.org/10.4049/jimmunol.2101076
Laura Richert
*University of Bordeaux, INSERM, Bordeaux Population Health Research Center, UMR1219, Bordeaux, France;
†Inria SISTM Team, Talence, France;
‡CHU de Bordeaux, Service d’Information Médicale, Bordeaux, France;
§Vaccine Research Institute, Créteil, France;
Jean-Daniel Lelièvre
§Vaccine Research Institute, Créteil, France;
¶INSERM U955, Université Paris-Est Créteil, Créteil, France;
‖Groupe Henri-Mondor Albert-Chenevier, AP-HP, Créteil, France;
Christine Lacabaratz
§Vaccine Research Institute, Créteil, France;
¶INSERM U955, Université Paris-Est Créteil, Créteil, France;
Lucile Hardel
*University of Bordeaux, INSERM, Bordeaux Population Health Research Center, UMR1219, Bordeaux, France;
§Vaccine Research Institute, Créteil, France;
Hakim Hocini
§Vaccine Research Institute, Créteil, France;
¶INSERM U955, Université Paris-Est Créteil, Créteil, France;
Aurélie Wiedemann
§Vaccine Research Institute, Créteil, France;
¶INSERM U955, Université Paris-Est Créteil, Créteil, France;
Frédéric Lucht
#CHU de Saint Etienne, Saint-Priest-en-Jarez, France;
**Université Jean Monnet and Université de Lyon, Saint-Etienne, France;
Isabelle Poizot-Martin
††Aix-Marseille Université, APHM, INSERM, IRD, SESSTIM, Sciences Economiques & Sociales de la Santé & Traitement de l’Information Médicale, ISSPAM, APHM Sainte-Marguerite, Service d’Immuno-Hématologie Clinique, Marseille, France;
Claire Bauduin
*University of Bordeaux, INSERM, Bordeaux Population Health Research Center, UMR1219, Bordeaux, France;
§Vaccine Research Institute, Créteil, France;
Alpha Diallo
‡‡INSERM-ANRS, Paris, France;
Véronique Rieux
§Vaccine Research Institute, Créteil, France;
‡‡INSERM-ANRS, Paris, France;
Elodie Rouch
*University of Bordeaux, INSERM, Bordeaux Population Health Research Center, UMR1219, Bordeaux, France;
§Vaccine Research Institute, Créteil, France;
Mathieu Surenaud
§Vaccine Research Institute, Créteil, France;
¶INSERM U955, Université Paris-Est Créteil, Créteil, France;
Cécile Lefebvre
§Vaccine Research Institute, Créteil, France;
¶INSERM U955, Université Paris-Est Créteil, Créteil, France;
Emile Foucat
§Vaccine Research Institute, Créteil, France;
¶INSERM U955, Université Paris-Est Créteil, Créteil, France;
Pascaline Tisserand
§Vaccine Research Institute, Créteil, France;
¶INSERM U955, Université Paris-Est Créteil, Créteil, France;
Lydia Guillaumat
§Vaccine Research Institute, Créteil, France;
¶INSERM U955, Université Paris-Est Créteil, Créteil, France;
Mélany Durand
*University of Bordeaux, INSERM, Bordeaux Population Health Research Center, UMR1219, Bordeaux, France;
†Inria SISTM Team, Talence, France;
§Vaccine Research Institute, Créteil, France;
Boris Hejblum
*University of Bordeaux, INSERM, Bordeaux Population Health Research Center, UMR1219, Bordeaux, France;
†Inria SISTM Team, Talence, France;
§Vaccine Research Institute, Créteil, France;
Odile Launay
§§CIC 1417 F-CRIN I-REIVAC, INSERM, Hôpital Cochin, AP-HP, Paris, France; and
¶¶Université Paris Descartes, Paris, France
Rodolphe Thiébaut
*University of Bordeaux, INSERM, Bordeaux Population Health Research Center, UMR1219, Bordeaux, France;
†Inria SISTM Team, Talence, France;
‡CHU de Bordeaux, Service d’Information Médicale, Bordeaux, France;
§Vaccine Research Institute, Créteil, France;
Yves Lévy
§Vaccine Research Institute, Créteil, France;
¶INSERM U955, Université Paris-Est Créteil, Créteil, France;
‖Groupe Henri-Mondor Albert-Chenevier, AP-HP, Créteil, France;